Sino Biopharmaceutical Limited (HKEX: 01177) launched SBP Group on Aug. 19, 2026, alongside first-half revenue growth of 10.6% to RMB 19.44 billion and core profit attributable to shareholders growth of 92.3% to RMB 3.34 billion, approximately $496.7 million. Reported net profit rose 1.4% to RMB 3.43 billion, affected by the comparison with dividend income from Sinovac Zhongwei. Revenue from innovative drugs and out-licensing increased 44.3% to RMB 8.79 billion, raising its share of total revenue to 45.2% from 34.7%, while management expects innovative drugs to contribute about 50% of full-year revenue. Out-licensing revenue alone rose roughly 21-fold to RMB 980 million, driven mainly by Sanofi's agreement for global rights to rovadicitinib, worth up to $1.53 billion including a $135 million upfront payment. The company said four multinational out-licensing transactions had potential aggregate value exceeding $7 billion. Shares rose more than 20% intraday on Aug. 20 and gained a further 3.62% to HK$5.585 in the morning session on Aug. 21 after Bank of America Securities raised its target to HK$7.1 from HK$6.2 and Citi lifted its target to HK$10.8 from HK$10, with both retaining Buy ratings. Sino Biopharmaceutical has invested about RMB 600 million in AI infrastructure and platforms over three years and is pursuing two-way globalization through international licensing, acquisitions and partnerships including GSK.